Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 0 results

Large-scale testing (Phase 3)Ended earlyNCT01953601
What this trial is testing

Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)

Who this might be right for
Amnestic Mild Cognitive ImpairmentAlzheimer's DiseaseProdromal Alzheimer's Disease
Merck Sharp & Dohme LLC 1,454
Testing effectiveness (Phase 2)Study completedNCT02423200
What this trial is testing

Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD

Who this might be right for
Alzheimer's Disease
EIP Pharma Inc 16
Testing effectiveness (Phase 2)Study completedNCT03319810
What this trial is testing

Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease

Who this might be right for
Mild Cognitive Impairment
Sutter Health 5
Testing effectiveness (Phase 2)Study completedNCT04032626
What this trial is testing

MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients

Who this might be right for
Cognitive Impairment, MildCognitive DysfunctionAmyloid Plaque+2 more
St. Joseph's Hospital and Medical Center, Phoenix 15
Testing effectiveness (Phase 2)Study completedNCT04498650
What this trial is testing

Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD

Who this might be right for
Early Alzheimers DiseaseMild Cognitive Impairment Due to AD
Vivoryon Therapeutics N.V. 259